Dr. Dyrda participates in an international study of central serous chorioretinopathy

Medical content revised by - Last revision 21/09/2020
Dr. Dyrda participates in an international study of central serous chorioretinopathy

Dr. Agnieszka Dyrda, member of the ICR’s Department of Retina and Vitreous and Department of Cataract, has published together with the European Society of Retina and Vitreous (EVRS) an article that evaluates at international level the different therapeutic approaches of this pathology and makes a review of the current literature on it.

The article, published in the prestigious medical journal Acta Ophthalmologica, presents the results of an international study that compares the daily clinical practice of 63 European centers and evaluates the characteristics of 1719 patients diagnosed with central serous chorioretinopathy.

What is central serous chorioretinopathy?

  • Central Serous Chorioretinopathy (CSC) is a disease of inflammatory origin that affects the choroid and the retina. Inflammation produces an increase in the permeability of the vessels, thus causing fluid to escape, which accumulates in the choroid and is retained in the barrier of the pygmentary epithelium. However, over time this barrier becomes ineffective and the fluid passes under the retina, eventually causing it to detach.
  • When the affected area of the retina is the central zone or macula, the patient may perceive diminished and blurred vision, as well as a static central dark spot (black or gray). This prevents or hinders reading and generates a distortion of lines and objects, which may seem smaller than they really are.
  • CSC is divided en two types: acute, which usually resolves spontaneously in 80-90% of cases; and chronic, which lasts more than 3 months. Although Central Serosal Chorioretinopathy is not a very common disease, in chronic cases it can endanger vision.
  • CSC affects mostly young men (46 years old according to the study) and older women (54 years old in the sample studied).

What does the article say?

This new study has gathered the best experts from 24 European countries, including Dr. Dyrda, to study the characteristics of this disease in the European population and the different therapeutic approaches used in these countries, such as the differences and similarities in the treatment of Central Serous Corioretinopathy.

The article is titled An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of the literature. The European Vitreoretinal Society central serous chorioretinopathy study and can be consulted on the website of Acta Ophthalmologica.

Related articles

Dr. Dyrda and Dr. Anton publish a study to improve the early detection of glaucoma

Dr. Agnieszka Dyrda, member of the ICR’s Department of Retina and Vitreous and Cataract Department, has participated together with Dr. Alfonso Antón, head of the Glaucoma Department, in a multicenter study recently published in the prestigious British Journal of Ophthalmology.

La Dra. Dyrda publica un artículo sobre la coriorretinopatía serosa central crónica

La Dra. Dyrda, miembro del Departamento de Retina y Vítreo y de Catarata del ICR, ha publicado en cooperación con los retinólogos de nuestro centro un artículo titulado «Características clínicas y evolución a largo plazo de la coriorretinopatía serosa central crónica» en Annals d’Oftalmologia, la revista de la Sociedad Catalana de Oftalmología. Este proyecto científico […]

La Dra. Agnieszka Dyrda gana el 2º premio en el 19º Congreso ESASO Retina Academy

La Dra. Agnieszka Dyrda fue galardonada durante el 19º Congreso ESASO Retina Academy por su trabajo sobre el diagnóstico de la neovascularización coroidea (NVC) mediante OCT-A en pacientes previamente diagnosticados de coroidopatía serosa central crónica (CSCC).

Cinco consejos para evitar lesiones oculares producidas por juguetes

Durante los últimos años varios estudios han alertado que algunos juguetes populares entre los más pequeños pueden estar asociados con lesiones oculares infantiles. Por ello es importante recordar algunos consejos de seguridad a la hora de elegir juguetes infantiles y juveniles estas Navidades.

Do you have any questions?

Contact us or request an appointment with one of our Retina and Vitreous specialists.

Visit us at:

ICR Pau Alcover

C. Pau Alcover 67
08017 Barcelona See map

ICR Ganduxer Headquarters

c/Ganduxer,117
08022 Barcelona See map

ICR Terrassa

77, Del Nord St.
08221 Terrassa See map

ICR Service at Clínica Ntra. Sra. del Remei

c/ de l'Escorial,148
08024 Barcelona See map

Clínica Bonanova Surgical Center

Passeig Bonanova, 22
08022 Barcelona See map

Clinica Bonanova Tests and Treatments

c/ Mandri, 63
08022 Barcelona See map

ICR Pau Alcover

Telephone number (+34) 93 378 23 19

Opening hours:
Monday to Friday from 8 am to 9 pm. Saturday from 8 am to 2 pm.

How to get there More information

ICR Ganduxer Headquarters

Telephone number 93 254 79 20
Emergencies phone number: 93 418 72 27

Opening hours:
Monday to Friday 8 a.m. to 9 p.m.
Saturdays 9 a.m. to 2 p.m.

How to get there More information

ICR Terrassa

Telephone number +34 93 736 34 40

Opening hours:
Monday to Friday from 8:30 a.m. to 2 p.m. and 3 p.m. to 8 p.m.
The center will be closed from August 3 to 23, both included. If you have an emergency, you can contact ICR Barcelona (C / Ganduxer, 117), where we have a 24-hour emergency service.

How to get there More information

ICR Service at Clínica Ntra. Sra. del Remei

Telephone number 902 10 10 50

Opening hours:
Every day from 3 p.m. to 8 p.m. and Friday mornings from 10 a.m. to 2 p.m.

How to get there More information

Clínica Bonanova Surgical Center

Telephone number 934 34 09 25

Opening hours:
Monday to Friday from 7:30 a.m. to 8:30 p.m.

How to get there More information

Clinica Bonanova Tests and Treatments

How to get there More information

This website uses cookies in order to collect statistical information regarding navigation. If you keep on surfing this website, it shall be deemed to have acknowledged its use. More information.